Kestra Medical Technologies, Ltd. KMTS R2K
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 180.0% over 5 years.
CONS
- Earnings shrank at -17.6% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KMTS Kestra Medical Technologies, Ltd. R2K | 21.26 | - | $1.24B | - | -41.10% | -92.65% | 179.99% | -17.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jul 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.78M | - | 15.09M | 17.23M | 19.37M | 22.57M | 24.55M |
| Cost of Revenue | - | - | 8.54M | 9.60M | 10.52M | 11.14M | 11.65M |
| Gross Profit | 4.20M | - | 6.55M | 7.63M | 8.85M | 11.42M | 12.91M |
| Operating Expenses | - | - | 27.15M | 55.84M | 37.73M | 43.18M | 47.67M |
| Operating Income | -18.43M | - | -20.60M | -48.21M | -28.88M | -31.75M | -34.77M |
| EBITDA | - | - | -18.07M | -47.41M | -21.85M | -28.48M | -30.26M |
| Interest Expense | - | - | 1.78M | 1.76M | 1.91M | 1.90M | 1.89M |
| Pretax Income | - | - | -21.74M | -51.01M | -25.79M | -32.75M | -34.13M |
| Tax Provision | - | - | 18.00K | 102.00K | 33.00K | 34.00K | 35.00K |
| Net Income | -19.88M | - | -21.51M | -52.05M | -25.83M | -32.78M | -34.17M |
| Diluted EPS | -1.12 | - | -0.50 | -2.21 | -0.50 | -0.64 | -0.61 |
| R&D Expense | 3.40M | 3.51M | 3.35M | - | 4.00M | 4.88M | 4.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Revenue | 7.63M | 27.81M | 59.81M |
| Cost of Revenue | 18.28M | 27.45M | 35.60M |
| Gross Profit | -10.65M | 362.00K | 24.21M |
| Operating Expenses | 69.77M | 85.42M | 130.59M |
| Operating Income | -80.42M | -85.06M | -106.38M |
| EBITDA | -73.74M | -76.31M | -97.98M |
| Interest Expense | 5.63M | 6.23M | 7.73M |
| Pretax Income | -84.22M | -94.10M | -113.68M |
| Tax Provision | 15.00K | 24.00K | 135.00K |
| Net Income | -84.24M | -94.12M | -113.81M |
| Diluted EPS | -4.36 | -5.07 | -5.13 |
| R&D Expense | - | 15.49M | 15.65M |
Compounded Sales Growth
| 5 Years: | 179.99% |
| 1 Year: | 62.70% |
Compounded Profit Growth
| 5 Years: | -17.56% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -5.60% |
| 6 Months: | -21.69% |
| 3 Months: | -8.68% |
| 1 Month: | +8.97% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Total Assets | 38.66M | 45.95M | 295.74M |
| Current Assets | 18.42M | 14.91M | 255.33M |
| Cash & Equivalents | 14.81M | 8.25M | 237.59M |
| Inventory | 2.11M | 3.29M | 6.57M |
| Receivables | 0 | 2.00M | 8.08M |
| Total Liabilities | 156.23M | 255.33M | 90.34M |
| Current Liabilities | 36.74M | 32.97M | 37.98M |
| Long Term Debt | 17.32M | 42.54M | 41.10M |
| Total Debt | 39.13M | 45.17M | 44.31M |
| Total Equity | -117.58M | -209.38M | 205.41M |
| Shares Outstanding | 49.53M | 49.53M | 51.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Operating Cash Flow | -69.64M | -72.23M | -77.61M |
| Investing Cash Flow | -15.46M | -12.23M | -23.31M |
| Financing Cash Flow | 96.11M | 77.72M | 330.26M |
| Capital Expenditure | -15.46M | -12.51M | -23.59M |
| Free Cash Flow | -85.10M | -84.75M | -101.20M |
| Net Change in Cash | 11.00M | -6.74M | 229.35M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Gross Margin % | -139.6% | 1.3% | 40.5% |
| Operating Margin % | -1,054.0% | -305.8% | -177.8% |
| Net Margin % | -1,104.0% | -338.4% | -190.3% |
| ROE % | 71.6% | 45.0% | -55.4% |
| ROCE % | -4,195.1% | -655.4% | -41.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 43.12% | 25.17M | $535.16M |
| 2 | Price (T.Rowe) Associates Inc | 10.22% | 5.97M | $126.89M |
| 3 | FMR, LLC | 9.80% | 5.72M | $121.63M |
| 4 | Andera Partners | 4.62% | 2.70M | $57.30M |
| 5 | Yu Fan | 3.91% | 2.28M | $48.53M |
| 6 | Brown Advisory Inc. | 2.95% | 1.72M | $36.65M |
| 7 | Blackrock Inc. | 2.89% | 1.69M | $35.91M |
| 8 | Eventide Asset Management LLC | 2.48% | 1.45M | $30.74M |
| 9 | Alliancebernstein L.P. | 2.26% | 1.32M | $28.07M |
| 10 | Franklin Resources, Inc. | 2.13% | 1.24M | $26.43M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KMTS